


# Planning and Implementation of Low-Dose Computed Tomography Lung Cancer Screening Programs in the United States

Rebecca Qiu, BSN, RN, Amy Copeland, MPH, Erica Sercy, MSPH, Nancy R. Porter, MS, Karen Kane McDonnell, PhD, RN, OCN®, and Jan Marie Eberth, PhD



© semnic/Stock/Thinkstock

**Background:** One of the largest, most expensive randomized, controlled trials, the National Lung Screening Trial, found that annual low-dose computed tomography (LDCT) scans led to a 20% reduction in lung cancer deaths.

**Objectives:** This study describes the characteristics and program implementation barriers experienced by LDCT screening programs in the United States.

**Methods:** Using a mixed-methods approach, Lung Cancer Alliance Screening Centers of Excellence were surveyed and interviewed in 2013. Representatives from 65 centers completed an electronic questionnaire, followed by in-depth interviews with 13 physicians and nurse navigators regarding their institution's screening programs.

**Findings:** Participants cited low patient demand and few physician referrals as barriers, but few centers reported needing additional staff or equipment. Those interviewed discussed the importance of a multidisciplinary team and overcoming barriers related to insurance reimbursement, costs, and physician knowledge to improve program implementation.

Rebecca Qiu, BSN, RN, is an RN at Cone Health in Greensboro, NC; Amy Copeland, MPH, is the director of medical outreach at Lung Cancer Alliance in Washington, DC; and Erica Sercy, MSPH, is a program coordinator I and Nancy R. Porter, MS, is a graduate assistant, both in the Cancer Prevention and Control Program in the Arnold School of Public Health, Karen Kane McDonnell, PhD, RN, OCN®, is an assistant professor in the School of Nursing, and Jan Marie Eberth, PhD, is an assistant professor in the Arnold School of Public Health, all at the University of South Carolina in Columbia. The authors take full responsibility for the content of the article. Qiu was supported in part by the Magellan Scholar Program at the University of South Carolina. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers or editorial staff. Eberth can be reached at [jmeberth@mailbox.sc.edu](mailto:jmeberth@mailbox.sc.edu), with copy to editor at [CJONEditor@ons.org](mailto:CJONEditor@ons.org). (Submitted January 2015. Revision submitted April 2015. Accepted for publication April 13, 2015.)

Key words: lung neoplasms; spiral computed tomography; early detection of cancer; health services research

Digital Object Identifier: 10.1188/16.CJON.52-58

The high incidence and mortality rates for lung cancer, coupled with a very low five-year survival rate of about 17%, demonstrate that lung cancer is a global health threat (Siegel, Naishadham, & Jemal, 2013). When diagnosed early, individuals have a greater chance of long-term survival, whereas late-stage lung cancer is difficult to treat successfully (Kathuria, Gesthaller, Spira, Brody, & Steiling, 2014; Siegel et al., 2013). However, findings from the National Lung Screening Trial (NLST) showed a 20% reduction in lung cancer-related death among those who underwent an annual screening with low-dose computed tomography (LDCT) compared to screening with a chest x-ray (National Lung Screening Trial Research Team, 2013).

In response to these results, recommendations for lung cancer screening are being refined by federal, professional, and nonprofit organizations with involvement in cancer prevention (American College of Radiology [ACR], 2013; American Lung Association, 2013; Jaklitsch et al., 2012; U.S. Preventive Services Task Force [USPSTF], 2015). USPSTF updated its screening recommendations in December 2013 to include annual LDCT screening for individuals at high risk for lung cancer (aged 55–80 years who have a smoking history of 30 or more pack-years and currently smoke or quit within the past 15 years) (USPSTF, 2015). In February 2015, the U.S. Centers for Medicaid and Medicare Services (CMS) issued its final coverage decision to offer full Medicare coverage of LDCT lung cancer screening for all